Nasdaq: ADAP

AdaptImmune Therapeutics PLC

Adaptimmune is a clinical stage biotechnology company focused on the development of T cell therapies to treat cancer. The company aims to utilize the body’s own immune system to target and destroy cancer by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses. It has one clinical stage asset and two preclinical stage assets all for the treatment of various forms of cancer. Its lead program is an engineered higher-affinity TCR targeting the NY-ESO-1 cancer testis antigen. ADAP is developing the NY-ESO TCR therapeutic candidate for treatment of patients with solid tumors and hematological malignancies including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer and esophageal cancer.

Foresite Capital believes that Adaptimmune has a unique technology that will make it an important player in the emerging field of immune-oncology.